Christina Washington to Ovarian Neoplasms
This is a "connection" page, showing publications Christina Washington has written about Ovarian Neoplasms.
Connection Strength
2.925
-
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review. Gynecol Oncol. 2026 Jan; 204:218-227.
Score: 0.611
-
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. Gynecol Oncol. 2025 Dec; 203:158-164.
Score: 0.607
-
Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse. Curr Oncol Rep. 2022 Dec; 24(12):1685-1693.
Score: 0.494
-
PARP inhibitors in the treatment of ovarian cancer: a review. Curr Opin Obstet Gynecol. 2021 02 01; 33(1):1-6.
Score: 0.437
-
Olaparib in the treatment of ovarian cancer. Future Oncol. 2019 Oct; 15(30):3435-3449.
Score: 0.396
-
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. Curr Opin Obstet Gynecol. 2019 02; 31(1):4-11.
Score: 0.380